{"id":"envarsus-oral-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus is a calcineurin inhibitor that suppresses T-lymphocyte activation and proliferation, preventing rejection in transplant recipients. The extended-release formulation in Envarsus allows for once-daily dosing with more stable drug levels compared to immediate-release tacrolimus, improving medication adherence and reducing fluctuations in immunosuppressive coverage.","oneSentence":"Envarsus is a prolonged-release formulation of tacrolimus that provides sustained immunosuppression by inhibiting calcineurin and T-cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:34.724Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of organ rejection in adult kidney transplant recipients"},{"name":"Prophylaxis of organ rejection in adult heart transplant recipients"},{"name":"Prophylaxis of organ rejection in adult liver transplant recipients"}]},"trialDetails":[{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT03249831","phase":"PHASE1","title":"A Blood Stem Cell Transplant for Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-01-04","conditions":"Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies","enrollment":3},{"nctId":"NCT05156710","phase":"PHASE2","title":"BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-09","conditions":"Transplant Rejection","enrollment":48},{"nctId":"NCT05621759","phase":"PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-09-07","conditions":"Graft Vs Host Disease","enrollment":27},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT03178149","phase":"PHASE1","title":"A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Astellas Institute for Regenerative Medicine","startDate":"2018-07-13","conditions":"Age-Related Macular Degeneration","enrollment":42},{"nctId":"NCT03605927","phase":"PHASE1","title":"CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-02-15","conditions":"Graft-versus-host-disease, GVHD, GVHD, Acute","enrollment":45},{"nctId":"NCT04629248","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Primary Membranous Nephropathy","enrollment":142},{"nctId":"NCT05806749","phase":"PHASE1","title":"Immunological Tolerance in Patients With Mismatched Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-07-07","conditions":"End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection","enrollment":16},{"nctId":"NCT06315309","phase":"PHASE2","title":"Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-15","conditions":"GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes","enrollment":29},{"nctId":"NCT06265584","phase":"PHASE2","title":"Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-08","conditions":"Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders","enrollment":56},{"nctId":"NCT02630628","phase":"PHASE3","title":"Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-12-05","conditions":"Lupus Nephritis","enrollment":130},{"nctId":"NCT05242315","phase":"PHASE4","title":"Extended-Release Tacrolimus Following Liver Transplantation","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2022-05-15","conditions":"Liver Transplant; Complications, Renal Insufficiency, Immunosuppressant Adverse Reaction","enrollment":94},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT06900777","phase":"NA","title":"Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-04-01","conditions":"Vitiligo, Child, Progressive Disease","enrollment":90},{"nctId":"NCT03769298","phase":"PHASE2, PHASE3","title":"CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2019-02-27","conditions":"Kidney Pancreas Transplantation","enrollment":20},{"nctId":"NCT03689075","phase":"PHASE4","title":"Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation","status":"TERMINATED","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2018-11-01","conditions":"Kidney Transplant Failure, Allosensitization, Immunosuppression","enrollment":35},{"nctId":"NCT03916380","phase":"","title":"Drug Interaction With Envarsus XR and Grapefruit Juice","status":"COMPLETED","sponsor":"Shirley M. Tsunoda","startDate":"2019-10-25","conditions":"Kidney Transplant; Complications, Drug Interaction Food","enrollment":11},{"nctId":"NCT04646356","phase":"PHASE2","title":"Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-10-20","conditions":"Hereditary Hemorrhagic Telangiectasia, Epistaxis Nosebleed","enrollment":10},{"nctId":"NCT02584647","phase":"PHASE1, PHASE2","title":"PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors","status":"TERMINATED","sponsor":"Gulam Manji","startDate":"2015-11-04","conditions":"Sarcoma, Malignant Peripheral Nerve Sheath Tumors","enrollment":39},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT03644485","phase":"PHASE4","title":"Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-10-21","conditions":"Kidney Transplant","enrollment":284},{"nctId":"NCT01410747","phase":"","title":"A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-04-10","conditions":"Lupus Nephritis","enrollment":1484},{"nctId":"NCT02159651","phase":"","title":"A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-04-01","conditions":"Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis","enrollment":179},{"nctId":"NCT02160054","phase":"","title":"Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-11-15","conditions":"the Maintenance Phase After Kidney Transplantation","enrollment":289},{"nctId":"NCT04503616","phase":"PHASE1, PHASE2","title":"Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-09-16","conditions":"Graft-versus-host Disease","enrollment":46},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":"Kidney Transplant Failure and Rejection","enrollment":20},{"nctId":"NCT04788641","phase":"PHASE1","title":"Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-30","conditions":"Hyperkalaemia","enrollment":62},{"nctId":"NCT03959241","phase":"PHASE3","title":"TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2019-06-25","conditions":"Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia","enrollment":431},{"nctId":"NCT03760263","phase":"PHASE4","title":"Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus","status":"COMPLETED","sponsor":"Sentara Norfolk General Hospital","startDate":"2020-01-16","conditions":"Transplant;Failure,Kidney","enrollment":46},{"nctId":"NCT04420195","phase":"PHASE2","title":"Envarsus XR in Lung Transplant","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-10-23","conditions":"Lung Transplant","enrollment":41},{"nctId":"NCT06044558","phase":"","title":"Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics","status":"COMPLETED","sponsor":"LI YAN","startDate":"2022-09-01","conditions":"Kidney Transplant Patients","enrollment":507},{"nctId":"NCT02661035","phase":"PHASE2","title":"Allo HSCT Using RIC for Hematological Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-03-09","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":156},{"nctId":"NCT00556933","phase":"PHASE4","title":"Improved Induction and Maintenance Immunosuppression in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-04-01","conditions":"End-stage Renal Disease","enrollment":180},{"nctId":"NCT01650545","phase":"PHASE1, PHASE2","title":"Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-07","conditions":"Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity","enrollment":21},{"nctId":"NCT03713645","phase":"PHASE4","title":"Dosing Strategies for de Novo Once-daily Extended Release Tacrolimus (LCPT) in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Temple University","startDate":"2018-11-12","conditions":"Kidney Transplant","enrollment":36},{"nctId":"NCT03289650","phase":"PHASE3","title":"Extended Release Tacrolimus vs. Twice-Daily Tacrolimus","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2017-09-05","conditions":"End Stage Renal Disease, Rejection of Renal Transplant","enrollment":29},{"nctId":"NCT02341274","phase":"PHASE1","title":"Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers","status":"COMPLETED","sponsor":"Indiana University","startDate":"2016-11-11","conditions":"Bioequivalence","enrollment":24},{"nctId":"NCT05202145","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-01-11","conditions":"Healthy","enrollment":61},{"nctId":"NCT05029310","phase":"PHASE4","title":"Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2021-09-01","conditions":"Hyperkalemia, Kidney Transplant","enrollment":13},{"nctId":"NCT05667922","phase":"","title":"Prognostic Model of TAC in the Treatment of MN","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-06","conditions":"Idiopathic Membranous Nephropathy","enrollment":50},{"nctId":"NCT05667896","phase":"","title":"Prognostic Model of GC/TAC in the Treatment of MN","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-06","conditions":"Idiopathic Membranous Nephropathy","enrollment":50},{"nctId":"NCT02345850","phase":"PHASE3","title":"Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Acute Leukemia, Myelodysplasia","enrollment":346},{"nctId":"NCT00096460","phase":"PHASE2, PHASE3","title":"Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2004-08","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":30},{"nctId":"NCT05221411","phase":"PHASE4","title":"Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2022-01-19","conditions":"Autoimmune Hepatitis","enrollment":86},{"nctId":"NCT05109390","phase":"PHASE1","title":"A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-07-27","conditions":"Healthy","enrollment":72},{"nctId":"NCT04023760","phase":"PHASE4","title":"Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2019-06-26","conditions":"Pharmacokinetics, Kidney Transplant, Lung Transplant","enrollment":14},{"nctId":"NCT03582878","phase":"PHASE4","title":"Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2004-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":238},{"nctId":"NCT01220856","phase":"PHASE2","title":"Reparixin in Pancreatic Islet Transplantation","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2010-07-28","conditions":"Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus","enrollment":9},{"nctId":"NCT02152345","phase":"PHASE4","title":"Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-06","conditions":"Implant or Graft; Rejection","enrollment":57},{"nctId":"NCT02540395","phase":"NA","title":"Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2015-03","conditions":"Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy","enrollment":184},{"nctId":"NCT04718311","phase":"NA","title":"Study on Treatment for Patients With Symptomatic Oral Lichen Planus","status":"COMPLETED","sponsor":"University of Catania","startDate":"2019-01-02","conditions":"Lichen Planus, Oral","enrollment":60},{"nctId":"NCT02954159","phase":"PHASE3","title":"Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2017-05-18","conditions":"Ulcerative Colitis","enrollment":4},{"nctId":"NCT03828682","phase":"PHASE4","title":"Veloxis de Novo Kidney Transplant ECSWD","status":"UNKNOWN","sponsor":"Simon Tremblay, PharmD, PhD","startDate":"2019-06-21","conditions":"Kidney Transplantation, Immunosuppression","enrollment":60},{"nctId":"NCT01713400","phase":"PHASE2","title":"Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02-25","conditions":"Graft vs. Host Disease","enrollment":54},{"nctId":"NCT03978494","phase":"PHASE1","title":"Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.","status":"WITHDRAWN","sponsor":"Sandoz","startDate":"2019-09-02","conditions":"Kidney Transplant","enrollment":""},{"nctId":"NCT02077556","phase":"PHASE4","title":"Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2014-04","conditions":"Drug Interaction Potentiation","enrollment":14},{"nctId":"NCT01875237","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-27","conditions":"Leukemia, Myeloma, Myeloproliferative Diseases","enrollment":3},{"nctId":"NCT00866879","phase":"PHASE4","title":"Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-06","conditions":"Renal Transplant Rejection","enrollment":275},{"nctId":"NCT03864250","phase":"NA","title":"Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-11-26","conditions":"Tacrolimus, Idiopathic Membranous Nephropathy, Clinical Trial","enrollment":124},{"nctId":"NCT00629122","phase":"PHASE4","title":"Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2008-02","conditions":"Kidney Failure, Chronic","enrollment":5},{"nctId":"NCT01116232","phase":"PHASE2","title":"Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2010-08","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":4},{"nctId":"NCT02115113","phase":"PHASE3","title":"REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-28","conditions":"Liver Transplantation","enrollment":78},{"nctId":"NCT02129881","phase":"PHASE1, PHASE2","title":"The ONE Study UK Treg Trial","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2014-04","conditions":"End-stage Renal Failure","enrollment":15},{"nctId":"NCT00078559","phase":"PHASE1, PHASE2","title":"Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2003-11","conditions":"Kidney Transplantation, Kidney Disease","enrollment":10},{"nctId":"NCT01246206","phase":"PHASE2","title":"Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2010-11","conditions":"Hematological Malignancies","enrollment":21},{"nctId":"NCT00899847","phase":"PHASE2","title":"Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-05","conditions":"Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma","enrollment":9},{"nctId":"NCT03083782","phase":"PHASE1","title":"Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2017-04-18","conditions":"Venous Thromboembolism, Pharmacokinetics, Healthy","enrollment":12},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT01998789","phase":"PHASE2","title":"Everolimus Post Orthotopic Liver Transplant","status":"UNKNOWN","sponsor":"Tomoaki Kato","startDate":"2013-10","conditions":"Orthotopic Liver Transplant","enrollment":50},{"nctId":"NCT00639717","phase":"PHASE2","title":"Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-03","conditions":"Graft Versus Host Disease","enrollment":48},{"nctId":"NCT00514982","phase":"PHASE2","title":"Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-08-07","conditions":"Hermanski-Pudlak Syndrome, Colitis, Cytokines","enrollment":""},{"nctId":"NCT00596947","phase":"PHASE4","title":"Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2005-10","conditions":"Transplants and Implants","enrollment":18},{"nctId":"NCT00612274","phase":"EARLY_PHASE1","title":"Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-10","conditions":"Stem Cell Transplantation","enrollment":26},{"nctId":"NCT00141037","phase":"PHASE1, PHASE2","title":"Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-03","conditions":"Kidney Diseases, Kidney Transplantation, Kidney Transplant","enrollment":130},{"nctId":"NCT00023244","phase":"PHASE2","title":"Steroid Withdrawal in Pediatric Kidney Transplant Recipients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-01","conditions":"End-Stage Renal Disease","enrollment":274},{"nctId":"NCT02799888","phase":"PHASE2","title":"Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2014-04","conditions":"Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation","enrollment":40},{"nctId":"NCT01187953","phase":"PHASE3","title":"Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2010-09","conditions":"Renal Failure","enrollment":543},{"nctId":"NCT01518153","phase":"PHASE2","title":"Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02","conditions":"Leukemia, Lymphoma, Myeloma","enrollment":16},{"nctId":"NCT00423826","phase":"","title":"Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2007-01","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00717678","phase":"PHASE3","title":"A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-12","conditions":"Kidney Transplantation, Transplantation Immunology, Host vs Graft Reaction","enrollment":73},{"nctId":"NCT00608244","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-11","conditions":"Liver Failure","enrollment":59},{"nctId":"NCT00496483","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-07","conditions":"Renal Failure","enrollment":60},{"nctId":"NCT00772148","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-10","conditions":"Liver Failure","enrollment":58},{"nctId":"NCT00765661","phase":"PHASE2","title":"Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2008-09","conditions":"Kidney Failure, Renal Failure","enrollment":63},{"nctId":"NCT02446431","phase":"EARLY_PHASE1","title":"Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence","status":"RECRUITING","sponsor":"Miller Children's & Women's Hospital Long Beach","startDate":"2014-07","conditions":"Solid Tumor","enrollment":20},{"nctId":"NCT01109914","phase":"PHASE4","title":"Mucosal Response in Immunocompromised Host","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2010-04","conditions":"Kidney Transplantation, Immunity","enrollment":51},{"nctId":"NCT02392780","phase":"PHASE2","title":"Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease","status":"UNKNOWN","sponsor":"moshe yeshurun","startDate":"2015-04","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT01435291","phase":"PHASE4","title":"AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2011-10","conditions":"Renal Transplantation","enrollment":45},{"nctId":"NCT00545402","phase":"PHASE4","title":"A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-11","conditions":"Liver Transplantation","enrollment":180},{"nctId":"NCT01049633","phase":"","title":"B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure","status":"NO_LONGER_AVAILABLE","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00810602","phase":"PHASE1, PHASE2","title":"Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Pavan Reddy, MD","startDate":"2009-01","conditions":"Hematologic Malignancies, Graft vs Host Disease","enrollment":61},{"nctId":"NCT02075242","phase":"PHASE4","title":"TO Compare the Triple Drug Therapy and Dual Therapy .","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2014-01","conditions":"HEPATITIS","enrollment":170},{"nctId":"NCT01609673","phase":"NA","title":"Study of Everolimus in de Novo Renal Transplant Recipients","status":"TERMINATED","sponsor":"Helady Pinheiro, MD, PhD","startDate":"2013-03","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":1},{"nctId":"NCT01154387","phase":"PHASE1, PHASE2","title":"Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection","status":"UNKNOWN","sponsor":"Tolera Therapeutics, Inc","startDate":"2010-07","conditions":"End Stage Renal Disease, Renal Transplant","enrollment":85},{"nctId":"NCT00296244","phase":"PHASE4","title":"Steroid Free Immunosuppression in Liver Transplantation","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2006-02","conditions":"Liver Cirrhosis, Liver Transplant Disorder","enrollment":40},{"nctId":"NCT00183248","phase":"PHASE1, PHASE2","title":"Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-09","conditions":"Kidney Transplantation, Kidney Disease, Kidney Failure","enrollment":9},{"nctId":"NCT00787761","phase":"PHASE2","title":"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2007-04","conditions":"Myeloproliferative Disorders, Kidney Cancer, Leukemia","enrollment":24},{"nctId":"NCT00147381","phase":"PHASE3","title":"Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection","status":"COMPLETED","sponsor":"Dr. Claudia Bösmüller","startDate":"2004-01","conditions":"Kidney Transplantation","enrollment":197},{"nctId":"NCT00316810","phase":"PHASE3","title":"Simultaneous Pancreas-kidney Transplantation With Campath Protocol","status":"COMPLETED","sponsor":"Dr. Claudia Bösmüller","startDate":"2006-04","conditions":"Pancreas-Kidney Transplantation","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Envarsus Oral Product","genericName":"Envarsus Oral Product","companyName":"Imperial College Healthcare NHS Trust","companyId":"imperial-college-healthcare-nhs-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Envarsus is a prolonged-release formulation of tacrolimus that provides sustained immunosuppression by inhibiting calcineurin and T-cell activation. Used for Prophylaxis of organ rejection in adult kidney transplant recipients, Prophylaxis of organ rejection in adult heart transplant recipients, Prophylaxis of organ rejection in adult liver transplant recipients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}